NTRK1 and cancer: AXL, a receptor tyrosine kinase of the TAM family, has also emerged as a promising therapeutic target in advanced cancers, including CRC, due to its frequent overexpression and central role in cell proliferation, invasion, metastasis, epithelial–mesenchymal transition, angiogenesis, therapy resistance, immunosuppression and inflammation.